Publications by authors named "Melanie S Hart"

Article Synopsis
  • The study evaluated the effectiveness of the 2023 myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) criteria in diagnosing inflammatory demyelinating conditions in both adults and children.
  • It analyzed data from 1,879 patients, confirming MOGAD in 16% of those tested, with follow-up averaging 3.6 years.
  • The new diagnostic criteria demonstrated high sensitivity (96.5%) and specificity (98.9%), with MOG-Ab testing showing slightly lower specificity in adults, indicating the new criteria may improve diagnosis accuracy.
View Article and Find Full Text PDF

Valid, responsive blood biomarkers specific to peripheral nerve damage would improve management of peripheral nervous system (PNS) diseases. Neurofilament light chain (NfL) is sensitive for detecting axonal pathology but is not specific to PNS damage, as it is expressed throughout the PNS and CNS. Peripherin, another intermediate filament protein, is almost exclusively expressed in peripheral nerve axons.

View Article and Find Full Text PDF

Although cerebrospinal fluid (CSF) biomarker testing is incorporated into some current guidelines for the diagnosis of dementia (such as England's National Institute for Health and Care Excellence (NICE)), it is not widely accessible for most patients for whom biomarkers could potentially change management. Here we share our experience of running a clinical cognitive CSF service and discuss recent developments in laboratory testing including the use of the CSF amyloid-β 42/40 ratio and automated assay platforms. We highlight the importance of collaborative working between clinicians and laboratory staff, of preanalytical sample handling, and discuss the various factors influencing interpretation of the results in appropriate clinical contexts.

View Article and Find Full Text PDF